ACOG

EX-99.1

2 ea028362201ex99-1.htm PRESS RELEASE ANNOUNCES FINANCIAL RESULTS FOR THE 2025 FISCAL YEAR DATED MARCH 26, 2026

Exhibit 99.1

Alpha Cognition Inc.

Nasdaq:

ACOG

1452 Hughes Road, Ste. 200

Grapevine, TX 65051

www.alphacognition.com

info@alphacognition.com

Alpha Cognition Inc. Reports Fiscal 2025 Financial Results and Provides Operational Update

Alpha Cognition generated fourth quarter 2025 ZUNVEYL net product revenue of $2.5 million, contributing to full year 2025 total revenue of $10.2 million

Fourth quarter bottles dispensed increased 62% quarter-over-quarter to 4,941, with December representing the strongest month since launch

Executed second national PBM contract and initiating three studies to further support ZUNVEYL’s positioning in long-term care Alzheimer’s patients

Cash and cash equivalents totaled $66 million at year-end 2025, supporting the company’s continued target of operating profitability in 2027

Company to host conference call and webcast today, March 26, at 4:30 p.m. ET

VANCOUVER,

B.C., Grapevine, TX, March 26, 2026. Alpha Cognition Inc. (ACOG: NASDAQ) (“Alpha Cognition”, “ACI”, or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update.

“2025 was a year of strong commercial execution for Alpha Cognition as we continued to build momentum for ZUNVEYL – the first new oral Alzheimer’s treatment approved in more than 15 years. In the fourth quarter, we saw strong growth in demand, with December representing our strongest month since launch. We’re encouraged by the increasing rates of repeat ordering, indicating ZUNVEYL is moving beyond initial trial and becoming increasingly integrated into routine management in long-term care,” said Michael McFadden, Chief Executive Officer of Alpha Cognition.

“Importantly, we also executed a second national PBM contract, bringing us to two of the four major PBMs relevant to long-term care. Combined with the consistent clinical feedback we’re hearing on ZUNVEYL’s tolerability and behavioral profile, we believe we are well positioned to continue driving adoption as payer pull-through improves in 2026. We enter the year well-capitalized and focused on expanding our commercial footprint, deepening prescriber engagement, and advancing toward operational profitability in 2027.”

ZUNVEYL

Commercial Performance

●Net ZUNVEYL Revenue: Generated approximately $2.5 million in net product revenue in the fourth quarter of 2025. Launch-to-date net product revenue through year-end 2025 was approximately $6.8 million. Total revenues for the year 2025 were approximately $10.2 million, inclusive of net product revenues and licensing revenue.

●Bottles Dispensed: Dispensed 4,941 bottles in Q4, representing 62% quarter-over-quarter growth. December was the strongest single sales month since launch selling 1,859 bottles.

●Expanding Prescriber Base and Adoption Expansion: Q4 prescribers increased 50% over the prior quarter. Cumulative homes with prescriptions increased 26% in Q4, an early indicator of broadening adoption in the long-term care setting.

●Commercial Reach: Sales team reached 1,986 homes in the quarter and have engaged with approximately 4,000 unique facilities since commercial launch.

●Payer progress: Executed a second national PBM agreement during the quarter and now has agreements with two of the four major PBMs relevant to the long-term care market.

Alpha Cognition Inc.

Nasdaq:

ACOG

1452 Hughes Road, Ste. 200

Grapevine, TX 65051

www.alphacognition.com

info@alphacognition.com

Recent and Upcoming Business, Clinical, and Operational Highlights

●Alpha Cognition will present new clinical data on ZUNVEYL at the upcoming American Association of Geriatric Psychiatrists (AAGP), and the Neuroscience Education Institute (NEI) Spring Congress in Q2 2026.

●Alpha Cognition continues to expect two product approvals ex-US via our partner, CMS, in Asia.

●Announced Issuance of additional U.S. patent covering ZUNVEYL dosing regimens.

●Enrollment is ongoing in the BEACON study, a real-world effectiveness study to evaluate the impact of ZUNVEYL on cognition, behavior, and tolerability in the long-term care setting.

●Plan to initiate CONVERGE study, a retrospective data analysis in the long-term care environment that will provide data on ZUNVEYL in long term care Alzheimer’s patients. The analysis will provide data from approximately 400 patients for ZUNVEYL in areas of tolerability, dosing, and polypharmacy.

●Plan to Initiate RESOLVE study, a phase 4 study in Alzheimer’s disease (“AD”) patients to assess ZUNVEYL effect on tolerability and behaviors associated with AD. The Company believes the data could be supportive of future regulatory discussions and will be utilized with physicians and payers to inform them on tolerability of ZUNVEYL

●Alpha Cognition plans

EX-99.1

2 ea021101101ex99-1_alpha.htm

PRESS RELEASE DATED AUGUST 12, 2024

Exhibit 99.1

Alpha Cognition Inc.

CSE: ACOG

1200-750 W Pender St,

Vancouver, BC V6C 2T8,

www.alphacognition.com

info@alphacognition.com

NEWS RELEASE

Alpha Cognition Announces Financial Results for the Second Quarter and Six Months Ended June 2024 and Provides Corporate Update

VANCOUVER, B.C., August 12, 2024. Alpha Cognition Inc. (OTCQB: ACOGF) (CSE: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today reported financial results for the second quarter and six months ended June 30, 2024, and provided a corporate update.

“The FDA approval of ZUNVEYL represents an important breakthrough for patients with Alzheimer’s disease. This approval marks a pivotal moment for our company, demonstrating our commitment to innovation and our ability to deliver life-changing therapies to patients. The second oral therapy approved this decade, ZUNVEYL’s dual MOA was designed to eliminate drug absorption in the gastrointestinal (GI) tract, potentially addressing certain tolerability issues with leading Alzheimer’s disease medications, combined with a long-term efficacy profile. Over the coming months, we will focus attention on preparing for the commercial launch of ZUNVEYL and bringing this innovative treatment to patients,” said Michael McFadden, the Company’s Chief Executive Officer.

Second Quarter 2024 Business Accomplishments and Corporate Highlights

●The Company announced that the U.S. Food and Drug Administration (FDA) has granted approval for ZUNVEYL® (benzgalantamine) previously known as ALPHA-1062, for the treatment of mild-to-moderate Alzheimer’s disease (AD). AD is a progressive brain disorder that slowly destroys memory, thinking skills, and eventually the ability to do simple tasks, like carry on a conversation. AD is the most common form of dementia affecting nearly 7 million people, and is the leading cause of nursing home admissions and deaths, with 70% of all nursing home residents suffering with AD.

●We continued progress in a pre-clinical study in partnership with Seattle Institute for Biomedical and Clinical Research to assess ALPHA-1062 intra nasal’s reduction of behavioral and functional deficits and brain-wide burden of neuropathology following single or multiple blasts compared to placebo and sham.

●We also, advanced our commercialization preparations for launching in the Long-Term Care (“LTC”) market segment. Our research has indicated that the acetylcholinesterase inhibitor prescription market in the U.S. from the LTC market is large, representing 36% of the over 11 million prescriptions filled in pharmacies each year and is characterized by both patient and practitioner dissatisfaction.

Alpha Cognition Inc.

CSE: ACOG

1200-750 W Pender St,

Vancouver, BC V6C 2T8,

www.alphacognition.com

info@alphacognition.com

Financial Highlights for Second Quarter and Six Months ended June 30, 2024 (Expressed in United States Dollars and prepared in conformity with U.S. Generally Accepted Accounting Standards) (Unaudited)

●Research and development (R&D) expenses were $0.9 million for the three months ended June 30, 2024, and $1.9 million for the six months ended June 30, 2024, compared to $1.3 million and $2.4 million in the same periods in 2023, respectively. R&D expenses decreased from the prior year primarily due to the completion of the main clinical trails for ZUNVEYL in AD and the majority of the NDA filing expenditures having been incurred during 2023.

●General and administrative (G&A), excluding non-cash expenses relating to accretion, amortization, depreciation, and share-based compensation, were $1.2 million for the three months ended June 30, 2024, and $4.4 million for the six months ended June 30, 2024, compared to $0.6 million and $1.3 million in the same periods of 2023 respectively. The increases in G&A expenses for both the three and the six months ended June 30, 2024, compared to the same periods in 2023 was primarily related to increased consulting fee costs, which included $2.3 million recognized for shares issued for services under the Spartan Capital consulting agreement, management fees and salaries and professional fees.

●Share-based compensation included in G&A was $0.2 million for the three months ended June 30, 2024, and $0.5 million for the full six months ended June 30, 2024, compared to $0.8 million and $1.0 million in the same periods of 2023, respectably. The higher share-based compensation during 2023 was primarily related to new stock option grants issued during that period, the repricing of previously issued stock options during the first quarter of 2023, and related fluctuations in the Company’s stock price over such periods.

●On August 31, 2023, the Company’s functional currency changed to the USD from the CAD; as such, the Company recorded a derivative liability on the warrants outs